Last updated: April 23, 2026
What is PROCOMP in pharmaceutical supply terms?
PROCOMP is a brand name that is used on different pharmaceutical products in different markets, and that creates a core barrier to mapping “suppliers” at the component level without first locking to a specific PROCOMP drug, strength, dosage form, and country/market.
Under patent and procurement standards, “suppliers” can mean:
- API (active pharmaceutical ingredient) suppliers
- Finished dosage manufacturer (CDMO/contract manufacturer)
- Packaging/label suppliers
- Excipients and device components (where applicable)
- Regulatory/MAH (marketing authorization holder) and distributor networks
With only the name PROCOMP and no drug identity (API), strength, dosage form, or jurisdiction, a complete and accurate supplier map cannot be produced.
What supplier categories can be identified reliably with PROCOMP alone?
None. A supplier list would require at minimum one of the following:
- a specific INN (generic name) or API name
- a specific ATC code
- a specific country market (so MAH and manufacturing sites can be matched to filings and registrations)
- a specific dosage form/strength (tablets, capsules, injections; unit strength)
- a specific regulatory label (package insert, outer carton, or EMA/FDA/PMDA dossier)
Since that information is not present, any named suppliers (API makers, CDMOs, or MAHs) would be speculative.
Which data sources normally establish PROCOMP suppliers
A correct, audit-ready supplier map typically uses one or more of:
- Regulatory registration databases (MAH, manufacturing site, batch-release testing location)
- Drug product labeling (manufacturer address, packager address)
- Patent family links (manufacturing process and approved sites sometimes referenced in assignments/licensing)
- Tender/wholesale catalogs for the relevant market
- Inspection databases that show site capacity and corporate ownership
Without the missing drug identity, these sources cannot be searched in a non-ambiguous way.
What can be concluded for business action
No supplier roster (API, CDMO, packaging, or MAH) can be validated for “PROCOMP” without tying the brand to a specific marketed drug product.
Key Takeaways
- “PROCOMP” alone is not enough to identify suppliers for an API, finished dosage manufacturer, or MAH in a way that can be used for R&D or investment diligence.
- A complete supplier map requires a specific PROCOMP product identity (INN/API, strength, dosage form, and market/jurisdiction).
- Any attempt to list suppliers at this stage would not be compliance-grade and would not support decision-making.
FAQs
-
Does “PROCOMP” correspond to one single drug product globally?
No. Brand names are reused across markets and can refer to different products.
-
What counts as a “supplier” in pharma due diligence?
API suppliers, contract manufacturing sites (finished dosage/CDMO), and sometimes packagers and MAHs/distributors tied to regulatory filings.
-
Can patent filings alone identify PROCOMP suppliers?
Sometimes, but only after the exact product and API are identified, so the correct patent family and applicant/manufacturer links can be matched.
-
Why can’t I get a supplier list from the brand name only?
Because supplier and manufacturing-site information is tied to the specific registered product, strength, dosage form, and jurisdiction.
-
What is the minimum product detail needed to build a supplier map?
A specific drug identity (INN/API) plus the relevant market (jurisdiction), and the dosage form/strength to match the correct registration and labeling.
References
[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
[2] EMA. European public assessment reports and product information (where applicable). (Accessed via EMA database).
[3] WHO. ATC/DDD index (for product coding when INN is known). (Accessed via WHO database).
